By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Gilead Sciences, Inc. 

333 Lakeside Drive

Foster City  California  94404  U.S.A.
Phone: 800-GILEAD-5 or 650-574-3000 Fax: 650-522-5800


SEARCH JOBS


Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

YEAR FOUNDED:

1987

LEADERSHIP:

CEO: John F. Milligan, PhD

Chief Scientific Officer: Norbert W. Bischofberger, PhD

CFO: Robin L. Washington

COO: Kevin Young

CLINICAL TRIAL:

Please click here for clinical trial information.


Key Statistics


Email:
Ownership: Public

Web Site: Gilead
Employees: 4,000
Symbol: GILD
 









Company News
9 Top Biotechs That Have Stashed Away a $133 Billion M&A Cashpile Overseas 4/27/2017 6:29:52 AM
Why Gilead (GILD) Should Pay Close Attention And Maybe Even Fear Allergan (AGN)'s NASH Program 4/25/2017 6:23:20 AM
Gilead (GILD): A Future Dividend Gold Mine At A Bargain Price 4/25/2017 6:08:59 AM
Gilead (GILD) Announces Scientific Presentations Demonstrating Efficacy Of Harvoni (Ledipasvir/Sofosbuvir) In Special Patient Populations With HCV Infection 4/24/2017 7:24:48 AM
Gilead (GILD)'s $600 Million NASH Deal Finally Bears Fruit 4/24/2017 7:01:59 AM
How This Iowa Biotech Could be a Perfect Match for M&A Hungry Gilead (GILD) 4/24/2017 5:37:20 AM
Gilead (GILD) Announces Scientific Presentations Demonstrating Efficacy Of Harvoni (Ledipasvir/Sofosbuvir) In Special Patient Populations With HCV Infection 4/21/2017 11:23:30 AM
Gilead (GILD) Presents Data At The International Liver Congress 2017 Supporting The Efficacy And Safety Of Vemlidy In Patients With Chronic Hepatitis B After 96 Weeks, And Also After Switching From Viread 4/21/2017 7:00:39 AM
Gilead (GILD) Presents Proof-Of-Concept Data For GS-0976 In Nonalcoholic Steatohepatitis (NASH) At The International Liver Congress 2017 4/21/2017 5:55:19 AM
Gilead (GILD) Presents Data At The International Liver Congress 2017 Supporting The Efficacy And Safety Of Vemlidy In Patients With Chronic Hepatitis B After 96 Weeks, And Also After Switching From Viread 4/20/2017 11:07:28 AM
12345678910...
//-->